Cancer Drug Design and Discovery

1st Edition

Editors: Stephen Neidle Stephen Neidle
Hardcover ISBN: 9780123694485
eBook ISBN: 9780080554952
Imprint: Academic Press
Published Date: 14th November 2007
Page Count: 496
110.00 + applicable tax
83.95 + applicable tax
102.00 + applicable tax
66.99 + applicable tax
Unavailable
Compatible Not compatible
VitalSource PC, Mac, iPhone & iPad Amazon Kindle eReader
ePub & PDF Apple & PC desktop. Mobile devices (Apple & Android) Amazon Kindle eReader
Mobi Amazon Kindle eReader Anything else

Institutional Access


Description

The ultimate source of information on the design of new anticancer agents, emphasizing small molecules, this newest work covers recent notable successes resulting from the human genome and cancer genomics projects. These advances have provided information on targets involved in specific cancers that are leading to effective medicines for at least some of the common solid tumors. Unique sections explain the basic underlying principles of cancer drug development and provide a practical introduction to modern methods of drug design. Appealing to a broad audience, this is an excellent reference for translational researchers interested in cancer biology and medicine as well as students in pharmacy, pharmacology, or medicinal and biological chemistry and clinicians taking oncology options.

Key Features

  • Covers both currently available drugs as well as those under development
  • Provides a clinical perspective on trials of new anticancer agents
  • Presents drug discovery examples through the use of case histories

Readership

Translational researchers interested in cancer biology and medicine. Students in pharmacy, pharmacology, or medicinal and biological chemistry, as well as clinicians taking oncology options.

Table of Contents

Section I. Basic Principles

  1. Modern cancer drug discovery: Integrating targets, technologies and treatments
  2. Preclinical pharmacology and in vivo models
  3. Clinical trial designs for more rapid proof-of-principle and approval
    Section II. Methodology
  4. Structural biology and anticancer drug design
  5. Natural product chemistry and cancer drug discovery
  6. Pharmacokinetics & ADME optimization in drug discovery
    Section III. Drugs in the clinic and laboratory
  7. Temozolomide: from cytotoxic to molecularly-targeted agent
  8. Camptothecins for drug design, cancer cell death and gene targeting
  9. Targeting thymidylate synthase by antifolate drugs for the treatment of cancer
    Section IV. New Agents
  10. Targeting inactive kinases: structure as a foundation for cancer drug discovery
  11. Cell cycle inhibitors in cancer: current status and future directions
  12. Inhibition of DNA repair as a therapeutic target
  13. Heat shock protein-90 inhibitors: targeting the cancer chaperone for combinatorial blockade of oncogenic pathways
  14. Heat shock protein-90-directed therapeutics and target validation
  15. Inhibitors of tumour angiogenesis
  16. The biology and oncology of RAF–ERK signalling P53 as a therapeutic target
    Section V. The reality of cancer drugs in the clinic
  17. Cancer drug resistance
  18. Failure Modes in Anticancer Drug Discovery and Development

Details

No. of pages:
496
Language:
English
Copyright:
© Academic Press 2008
Published:
Imprint:
Academic Press
eBook ISBN:
9780080554952
Hardcover ISBN:
9780123694485

About the Editor

Stephen Neidle

Stephen Neidle, DSc, PhD, ARCS, FRSC, Director of Cancer Research UK Biomolecular Structure Group, Director of the Centre for Cancer Medicines, Professor of Chemical Biology, The School of Pharmacy, University College London, UK

Affiliations and Expertise

The School of Pharmacy, University College London, UK

Stephen Neidle

Stephen Neidle, DSc, PhD, ARCS, FRSC, Director of Cancer Research UK Biomolecular Structure Group, Director of the Centre for Cancer Medicines, Professor of Chemical Biology, The School of Pharmacy, University College London, UK

Affiliations and Expertise

The School of Pharmacy, University College London, UK

Reviews

The ultimate source of information on the design of new anticancer agents, emphasizing small molecules, this newest work covers recent notable successes resulting from the human genome and cancer genomics projects. These advances have provided information on targets involved in specific cancers that are leading to effective medicines for at least some of the common solid tumors. Unique sections explain the basic underlying principles of cancer drug development and provide a practical introduction to modern methods of drug design. Appealing to a broad audience, this is an excellent reference for translational researchers interested in cancer biology and medicine as well as students in pharmacy, pharmacology, or medicinal and biological chemistry and clinicians taking oncology options.